Drugs Containing Excipient (Inactive Ingredient) PHENYLALANINE

« Back to Dashboard

Branded drugs containing PHENYLALANINE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cardinal Health 107 LLC	PREVACID	lansoprazole	55154-0253	PHENYLALANINE

Generic drugs containing PHENYLALANINE excipient

Company	Ingredient	NDC	Excipient
Pfizer Laboratories Div Pfizer Inc	epoetin alfa-epbx	0069-1305	PHENYLALANINE
Cardinal Health 107 LLC	lansoprazole	55154-0253	PHENYLALANINE
Vifor (International) Inc	epoetin alfa-epbx	59353-002	PHENYLALANINE
CellTrans Inc	donislecel	73539-001	PHENYLALANINE
Abeona Therapeutics Inc	prademagene zamikeracel	84103-007	PHENYLALANINE

Phenylalanine Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: October 1, 2026

Phenylalanine is a specialty amino-acid excipient and formulation component with a small pharmaceutical market relative to its food, nutrition, and diagnostic applications. Demand is tied less to finished-drug volume than to amino-acid parenteral nutrition, oral nutritional products, taste-masking systems, and selected formulation platforms. The market has no transparent standalone revenue benchmark because suppliers report phenylalanine within broader amino-acid, pharmaceutical excipient, or nutrition portfolios.

The financial outlook is stable to moderately positive. Volume growth is likely to remain limited, while revenue growth depends on pharmaceutical-grade supply, fermentation efficiency, impurity control, regulatory documentation, and customer qualification. Commodity L-phenylalanine used in food and supplements creates price pressure. Pharmaceutical-grade material supports higher margins but faces long qualification cycles and limited customer concentration.

What is phenylalanine used for in pharmaceutical formulations?

Phenylalanine is an aromatic essential amino acid used primarily as a nutritional ingredient rather than as a conventional tablet excipient.

Primary pharmaceutical and medical uses

Use	Form of phenylalanine	Commercial relevance
Parenteral nutrition	Usually L-phenylalanine	Established use in amino-acid injections
Oral nutritional products	L-phenylalanine	Larger volume, lower pricing
Amino-acid blends	L-phenylalanine	Used in clinical nutrition and specialty diets
Taste and formulation studies	L- or D/L-phenylalanine	Limited, product-specific use
Peptide and drug-development research	Protected derivatives or specialty grades	Small, high-value demand
Diagnostic and metabolic products	L-phenylalanine	Niche demand linked to phenylketonuria testing

L-phenylalanine is the commercially dominant form. D-phenylalanine and racemic mixtures have more limited pharmaceutical relevance and are generally associated with specialty chemistry, research, or specific drug-development applications.

Phenylalanine has an important safety limitation. Patients with phenylketonuria, or PKU, cannot adequately metabolize phenylalanine. FDA labeling rules require warnings for products that contain phenylalanine in relevant circumstances, particularly products containing the artificial sweetener aspartame, which metabolizes to phenylalanine.[1]

How large is the pharmaceutical phenylalanine market?

No authoritative public dataset isolates pharmaceutical phenylalanine revenue from food, dietary supplement, amino-acid nutrition, and laboratory applications. Public market reports often combine phenylalanine with other amino acids or classify it under pharmaceutical excipients, which makes headline market values difficult to validate.

The commercial market can be divided into three tiers:

1. Pharmaceutical-grade L-phenylalanine for parenteral nutrition and regulated formulations.
2. Food, supplement, and sports-nutrition material.
3. Research, diagnostic, and specialty chemical grades.

The pharmaceutical segment is likely the smallest by volume but one of the highest-value segments on a per-kilogram basis. Buyers pay for:

• Compendial compliance.
• Low endotoxin and bioburden levels.
• Tight control of related amino acids and organic impurities.
• Batch traceability.
• GMP manufacturing.
• Regulatory support files.
• Reliable delivery over multi-year supply periods.

Public companies generally do not disclose phenylalanine revenue separately. The financial trajectory must therefore be assessed through demand drivers, pricing, production economics, and supplier qualification rather than reported segment revenue.

What drives phenylalanine excipient demand?

Parenteral nutrition demand

Parenteral nutrition is the most defensible pharmaceutical demand base. Amino-acid injection products use balanced amino-acid profiles, and phenylalanine is included as an essential amino acid. Growth is linked to hospital nutrition, neonatal care, oncology support, intensive care, and home parenteral nutrition.

This demand is relatively defensive because product substitution requires formulation review, regulatory documentation, and manufacturing changes. Volume growth is usually gradual rather than rapid.

Specialty nutrition

Medical foods and metabolic products create a more specialized demand profile. Phenylalanine is excluded from products intended for PKU patients, but it is included in general amino-acid nutrition and may be relevant to products for other nutritional conditions.

Pharmaceutical development

Phenylalanine can be used in peptide chemistry, amino-acid derivatives, and formulation research. These applications generate higher margins but do not create the same recurring volume as parenteral nutrition.

Manufacturing and supply-chain demand

Fermentation is the principal commercial production route for L-phenylalanine. Producers convert carbohydrate feedstocks through microbial or enzymatic processes, followed by separation, purification, crystallization, and drying. Fermentation economics depend on:

• Sugar and feedstock costs.
• Energy prices.
• Fermentation yield.
• Downstream purification costs.
• Waste-treatment requirements.
• Plant utilization.
• Regional environmental controls.

The supply chain is more exposed to Asian production capacity than to pharmaceutical demand alone. This creates a mismatch: demand can remain stable while prices decline when regional capacity expands.

How does phenylalanine compare with competing pharmaceutical amino acids?

Phenylalanine competes indirectly with other amino acids in nutrition products, but it does not have a direct substitute in a balanced amino-acid formulation.

Amino acid	Pharmaceutical role	Relative market characteristic
L-phenylalanine	Essential amino acid in nutrition formulations	Specialty, safety-sensitive
L-leucine	Nutritional and muscle-protein applications	Larger commercial demand
L-valine	Parenteral and nutritional formulations	Broad amino-acid demand
L-isoleucine	Parenteral and nutritional formulations	Established bulk market
L-tyrosine	Specialty nutrition and formulation use	More limited solubility and supply
L-glutamine	Clinical nutrition and specialty products	Larger development and nutrition profile

Phenylalanine has lower solubility than several aliphatic amino acids. That property can complicate concentrated liquid formulations and may increase the need for process control, pH management, or blending optimization. Its PKU warning also limits use in certain patient populations.

What is the FDA regulatory status of phenylalanine as an excipient?

Phenylalanine is not generally treated as an active pharmaceutical ingredient when it is included as a nutritional component in an amino-acid formulation. Its regulatory treatment depends on the product category, dosage form, route of administration, concentration, and intended use.

Relevant regulatory pathways include:

• FDA-approved parenteral nutrition products.
• Pharmaceutical formulations containing amino-acid mixtures.
• Medical foods and specialized nutrition products.
• Dietary supplements.
• Research and development materials.

The FDA Inactive Ingredient Database is the principal reference for inactive ingredients used in approved drug products. Presence in the database is product- and route-specific; it does not create a blanket approval for every concentration or dosage form.[2]

For a new pharmaceutical formulation, sponsors generally need to establish identity, purity, manufacturing controls, safety, specifications, and suitability for the proposed route. A supplier’s certificate of analysis alone is not sufficient for a high-risk sterile product.

What patents protect phenylalanine pharmaceutical supply?

The core L-phenylalanine molecule is old and is not protected by an active composition-of-matter patent. The principal intellectual-property risks concern manufacturing and formulation.

Manufacturing patents

Potentially protectable areas include:

• Engineered microbial strains.
• Fermentation media and feed strategies.
• Enzymatic conversion processes.
• Chiral resolution.
• Crystallization and purification.
• Endotoxin reduction.
• Continuous or intensified fermentation.
• Waste reduction and recovery systems.

These rights are often difficult to evaluate from public pharmaceutical patent databases because suppliers may use trade secrets rather than disclose process details. Process patents can remain commercially relevant even when the molecule itself is unpatented.

Formulation and method-of-use patents

Formulation patents may cover:

• Stable amino-acid injection compositions.
• Concentrated solutions.
• Compatibility with other nutrients.
• Pediatric or neonatal nutrition formulations.
• Specific pH ranges or excipient combinations.
• Controlled-release or taste-masked products.

These patents generally protect the finished formulation, not phenylalanine as a standalone material.

When does phenylalanine lose exclusivity?

Phenylalanine has no meaningful molecule-level exclusivity timeline. It is an established amino acid available from multiple producers.

Exclusivity may still apply to individual products through:

• Formulation patents.
• Manufacturing patents.
• New medical-food compositions.
• Delivery technologies.
• Regulatory exclusivity associated with a finished product.

Those rights must be analyzed at the product level. An ingredient supplier cannot rely on phenylalanine itself to block competition.

What is the Orange Book status of phenylalanine?

Phenylalanine is not expected to have a standalone Orange Book listing because the Orange Book identifies approved drug products and patent or exclusivity information associated with those products, not ordinary excipient commodities.[3]

If phenylalanine is present in an approved product, any Orange Book patent listing would generally relate to the finished drug, formulation, method of use, or delivery system. It would not automatically create patent protection over commercial phenylalanine supply.

Are there Paragraph IV challenges or biosimilar risks?

Phenylalanine itself does not face Paragraph IV challenges because it is not a patented small-molecule drug product with a standalone abbreviated new drug application pathway.

Biosimilar risk is also not applicable. Phenylalanine is a defined small molecule, not a biologic. Competitive risk instead comes from:

• Alternative suppliers.
• Regional fermentation capacity.
• Contract-manufacturing expansion.
• Qualification of lower-cost producers.
• Substitution among amino-acid blend suppliers.
• Finished-product reformulation.

Generic entry can affect demand indirectly when injectable nutrition products face price competition. The risk is product-specific and does not arise from a generic version of phenylalanine itself.

Which companies compete in pharmaceutical-grade phenylalanine?

The market includes large amino-acid manufacturers, Japanese and European specialty producers, Chinese fermentation companies, and distributors that offer pharmaceutical-grade material.

Companies active in broader amino-acid and pharmaceutical ingredient markets include Ajinomoto, Kyowa Hakko Bio, Evonik, and regional Chinese manufacturers. Their commercial exposure differs by grade, geography, and end market. Not every producer of food-grade phenylalanine is qualified for sterile pharmaceutical applications.

Supplier selection normally depends on:

• DMF or equivalent regulatory support.
• GMP status.
• Compendial compliance.
• Audit history.
• Sterility and endotoxin controls where applicable.
• Dual-sourcing capability.
• Change-control discipline.
• Capacity reservation.
• Ability to support global filings.

How strong is the phenylalanine patent estate?

The patent estate is weak at the molecule level and moderate in selected manufacturing and formulation niches.

IP category	Strength	Commercial implication
Composition of matter	Low	No meaningful molecule exclusivity
Fermentation processes	Moderate to high	Can protect yield and cost advantages
Purification	Moderate	May support quality and scale advantages
Sterile formulations	Moderate	Product-specific protection
Medical-food formulations	Moderate	Narrow, use-specific rights
Supplier know-how	High practical value	Often protected as trade secret
Finished-drug patents	Variable	Depends on product and sponsor

The most important barriers are often operational rather than legal. A qualified supplier with validated analytical methods, a reliable change-control system, and a history of regulatory acceptance can retain customers even without broad patent protection.

What is the financial trajectory for phenylalanine suppliers?

The likely trajectory is volume-stable with selective margin expansion in pharmaceutical-grade material and margin compression in commodity grades.

Base case

• Stable demand from parenteral and clinical nutrition.
• Low single-digit volume growth.
• Price competition in food and supplement grades.
• Moderate premium retention for GMP and compendial material.
• Continued supplier consolidation at the qualified pharmaceutical end.

Upside case

• Increased hospital and home parenteral nutrition demand.
• New amino-acid delivery systems.
• Higher regulatory barriers for low-cost producers.
• Expanded use in specialty peptide or injectable products.
• Improved fermentation yields and downstream recovery.

Downside case

• Excess Asian capacity.
• Feedstock inflation without corresponding price increases.
• Customer qualification of lower-cost suppliers.
• Reduced parenteral nutrition volumes.
• Product reformulation that lowers phenylalanine content.
• Quality failures that trigger recalls or supplier delisting.

Revenue growth should not be confused with market expansion. A supplier can increase revenue through higher pharmaceutical-grade pricing, documentation fees, or contract manufacturing while total phenylalanine volume remains flat.

What generic launch risks affect phenylalanine demand?

The principal generic risk is indirect. When a finished injectable nutrition product loses product-level exclusivity, generic competition can reduce selling prices and procurement budgets. Ingredient volumes may remain stable, but suppliers may face price renegotiation.

Launch risk is highest where:

• The product has a small number of approved suppliers.
• The formulation is easy to replicate.
• The amino-acid profile is not clinically differentiated.
• Hospital tenders emphasize lowest cost.
• Multiple producers have equivalent regulatory documentation.

Launch risk is lower where the supplier is embedded in a sterile manufacturing network and has been qualified for a critical injectable product.

What licensing deals affect phenylalanine?

Public licensing activity specifically tied to phenylalanine is limited. Commercial arrangements are more likely to involve:

• Long-term supply agreements.
• Private-label manufacturing.
• Regional distribution.
• Technology transfer for fermentation.
• Co-development of amino-acid formulations.
• Contract manufacturing of nutrition products.

The absence of widely disclosed licensing deals reflects the commodity and process-driven nature of the market. Commercial advantage is usually created through capacity, cost, quality systems, and customer qualification rather than a branded patent license.

What geographic markets matter most?

Asia is central to manufacturing capacity and price formation. Japan has a strong position in fermentation technology and high-quality amino-acid production. China is important for production scale and cost competition. North America and Europe remain important as regulated end markets with higher documentation requirements.

Geographic risks include:

• Import dependence.
• Tariffs and customs delays.
• Regional GMP inspections.
• Supply interruption.
• Currency movement.
• Environmental restrictions on fermentation plants.
• Customer requirements for dual sourcing.

A global pharmaceutical customer is likely to value a second qualified source even when the backup supplier has a higher nominal price.

Key Takeaways

• Phenylalanine is a specialty pharmaceutical amino acid, not a conventional high-value drug excipient.
• Pharmaceutical demand is anchored by parenteral nutrition and regulated amino-acid formulations.
• Public revenue and market-size data are not sufficiently granular for a reliable standalone market estimate.
• L-phenylalanine is the dominant commercial form.
• The molecule has no meaningful composition-of-matter exclusivity.
• Manufacturing know-how, fermentation efficiency, purification, and GMP qualification create the main competitive barriers.
• Paragraph IV and biosimilar risks do not apply to phenylalanine as an ingredient.
• Finished-product generic competition can pressure supplier pricing indirectly.
• The likely financial outlook is stable volume growth with stronger margins in qualified pharmaceutical grades and weaker margins in commodity grades.
• Supplier quality systems and regulatory acceptance are more important than broad patent ownership.

FAQs About Phenylalanine Pharmaceutical Supply

Is phenylalanine an active pharmaceutical ingredient or an excipient?

It can be either a nutritional active component or an excipient-like formulation ingredient, depending on the product’s intended purpose and regulatory classification. In amino-acid injections, it is generally included for nutritional function rather than pharmacological activity.

Can phenylalanine be used in injectable drugs?

Yes. L-phenylalanine is used in amino-acid parenteral nutrition products, subject to formulation-specific quality, sterility, endotoxin, and regulatory requirements.

Why is pharmaceutical-grade phenylalanine more expensive than food-grade material?

Pharmaceutical-grade material requires tighter specifications, documented GMP controls, validated testing, traceability, regulatory support, and often more stringent microbiological controls.

Does phenylalanine require a drug master file?

A drug master file or comparable regulatory package may be used when a supplier supports an approved drug product. Whether one is required depends on the sponsor’s regulatory strategy, product type, route of administration, and regional requirements.

What is the main investment risk in phenylalanine production?

The primary risk is oversupply in fermentation-based production, particularly when lower-cost capacity expands faster than pharmaceutical and nutrition demand. Margin pressure is more likely than a sharp collapse in total demand.

References

1. U.S. Food and Drug Administration. (2023). Food labeling: Revision of the nutrition and supplement facts labels. https://www.fda.gov/food/food-labeling-nutrition
2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredient
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
4. U.S. Food and Drug Administration. (n.d.). Drug master files. https://www.fda.gov/drugs/forms-submission-requirements/drug-master-files-guidelines
5. National Library of Medicine. (n.d.). L-Phenylalanine. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/L-Phenylalanine